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Introduction
Halitosis is a general term used to describe an 
unpleasant odour from the breath. In around 90% of 
cases the problem is attributable to volatile sulphur 
compounds (VSC) produced by anaerobic bacteria in 
the oral cavity [1], a condition that has been defined as 
intra oral halitosis [2]. The VSCs found in the mouth 
are mainly hydrogen sulphide, methyl mercaptan and 
dimethyl sulphide, and these have an unpleasant odour 
even in small concentrations [1]. Epidemiological 
evidence on persistent halitosis is limited and difficult 
to evaluate due to a lack of uniformity in measurement 
and diagnosis, and the data is often based on self-
estimation, limiting its accuracy [3]. However, the 
prevalence of halitosis in the general public is estimated 
at around 30% [4–7].
Organoleptic scoring by a trained odour judge is 
considered the gold standard for assessing breath odour 
[3, 8–12]. Though subjective and hard to standardise, 
the organoleptic score (OLS) is a direct measure of the 
extent of halitosis, and hence is the measure of most 
importance to the patient [2]. Commercially available 
devices such as the OralChroma gas chromatograph 
and Halimeter provide objective measures of VSC, 
known to be the principal component of breath odour, 
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Abstract
Halitosis occurs in approximately 30% of the adult population and has a negative social and 
psychological impact on affected individuals. Mouthwashes may be used to prevent unpleasant 
odour, with long-duration of effect being a desirable attribute. The aim of this study was to assess 
the long-term efficacy of CB12 (a mixture of 0.3% zinc acetate and 0.025% chlorhexidine) for the 
treatment of intra-oral halitosis. Thirty-four subjects with confirmed intra-oral halitosis were 
randomized into a double-blind, controlled, cross-over study to one of 2 groups; (i) CB12–water–
water or (ii) water–CB12–CB12. Each group comprised 3 treatments, each given evening and 
morning (12 h apart) on consecutive study days, with a 5 d washout between treatments. Intra-
oral halitosis was assessed objectively by measuring concentrations of hydrogen sulphide, methyl 
mercaptan, dimethyl sulphide and total volatile sulphur compound (VSC) concentrations and 
subjectively using organoleptic score (OLS). These were measured at baseline, 12 h after the evening 
rinse (i.e. 12 h overnight assessment) and 12 h after the daytime rinse (i.e. 12 h day time assessment). 
CB12 significantly reduced mean hydrogen sulphide, methyl mercaptan, dimethyl sulphide and VSC 
concentrations, with a duration of effect lasting 12 h, whether assessed overnight (all p  ⩽  0.0003 
versus water) or during the day (all p  ⩽  0.0007 versus water). CB12’s effect on OLS was also evident 
for 12 h overnight (p  =  0.0043). CB12 was well-tolerated. In conclusion, CB12 showed a clear and 
durable effect on intra-oral halitosis which lasted at least 12 h, both during the day and overnight, 
with consistent effect on both objective and subjective variables.
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and have been shown to correlate well with organolep-
tic assessment [12–14].
Recommended treatment needs for halitosis have 
been defined by an international consensus group based 
on earlier publications [2, 15, 16]. As well as profes-
sional treatments, home-based oral hygiene measures 
including tongue cleaning and the use of antibacterial 
mouthwashes are recommended [2]. A recent system-
atic review of the literature by Blom et al [17] concluded 
that nearly all mouthwashes with active ingredients 
helped to reduce bad breath, but the most compel-
ling evidence was for those containing chlorhexidine, 
cetyl pyridinium and zinc. Mouthwashes containing a 
combination of zinc ions and chlorhexidine have been 
shown to be particularly effective in inhibiting the for-
mation of VSCs [18–21]. However, mouthwashes 
containing high concentrations of chlorhexidine 
have been associated with a number of unwanted side 
effects such as irritation to oral mucosa, burning sen-
sations, tooth staining and unpleasant or altered taste, 
precluding their long-term use [18, 22, 23].
CB12 (MEDA OTC, Sweden) is a commercially 
available, over-the-counter mouthwash, containing 
a combination of two active ingredients: zinc acetate 
(0.3%) and a low concentration of chlorhexidine 
(0.025%). Previous studies with CB12 have shown it to 
be effective in treating halitosis by neutralising hydro-
gen sulphide, methyl mercaptan and dimethyl sulphide 
[19, 24, 25]. Thrane et al [19] tested CB12 in 19 healthy 
volunteers in a non-randomised, one way cross-over, 
open label trial and found significantly greater inhibi-
tion of VSC production compared with rinsing with 
water. A four-week follow-up of a sub-group of sub-
jects in the same study found that daily use of CB12 
did not cause tooth discolouration or other side effects 
such as mucosal lesions or taste disturbance. In a dou-
ble blind, 6-fold crossover study in 14 healthy adults 
with a baseline OLS  >  2 on the study morning, CB12 
showed clear superiority in improving OLS and reduc-
ing mean VSC levels versus other mouthwashes and 
water over a short observation period (between 30 min 
and 3 h) [24]. A more recent trial found no halitosis 
(identified by VSC assessment) at day 14 in 12 out of 
21 subjects using a zinc and chlorhexidene rinse, com-
pared with 1 of 21 using a negative control rinse [25].
The present study was conducted in order to evalu-
ate the duration of effect of CB12 within the rigorous 
setting of a randomised, controlled, double-blind trial 
in subjects with intra-oral halitosis under highly stand-
ardized conditions.
Methods
The study was conducted in agreement with the 
following directives, laws, and guidelines: the 
Declaration of Helsinki; ICH guideline on Good 
Clinical Practice (ICH E6); EU Cosmetic Products 
Regulation No 1223/2009; and The Scientific 
Committee on Consumer Safety’s Notes of Guidance 
for Testing of Cosmetic Ingredients and their Safety 
Evaluation [26]. The study was ethically approved in 
accordance with German regulations.
Study population
Participants were recruited from dental study sites 
in Germany with a halitosis out-patient department. 
Subjects were eligible for inclusion if they were otherwise 
healthy, but had halitosis of intra-oral origin with daily 
periods of noticeable halitosis. They were required 
to have an OLS  ⩾  2 (Rosenberg Score adapted by 
Greenman) [11] prior to the first dose of study treatment 
of each study period. Subjects were also required to have a 
total VSC concentration  >160 ppb, a hydrogen sulphide 
concentration  ⩾112 ppb and a methyl mercaptan 
concentration  ⩾26 ppb prior to the first dose of study 
treatment at the first study period. Written informed 
consent was obtained from all subjects prior to 
enrolment.
Individuals were excluded from the study if they 
had a history of reactions to alcohol or any of the 
ingredients of study treatment; extra-oral halitosis, 
as indicated by lack of significant difference between 
the results of organoleptic assessments from nasal and 
oral breath; periodontitis with a periodontal screening 
and recording index  >Code 2 in more than one sex-
tant [11]; open caries lesions  >D2; obvious gingival 
inflammation, gingivitis or advanced periodontitis; 
oral thrush; history of malignant or infectious diseases; 
systemic medication associated with oral dryness 
within 1 month prior to, or during, the study period; 
use of mouth care products containing chlorhexidine 
or zinc compounds  <2 weeks before first study treat-
ment; or systemic antibiotic therapy within the preced-
ing 3 months.
Study treatments
CB12 contains 0.3% zinc acetate dihydrate, 0.025% 
chlorhexidine diacetate, aqua, glycerin, hydrogenated 
starch hydrolysate, alcohol, sodium fluoride, PEG-40 
hydrogenated castor oil, potassium acesulfame, citric 
acid and aroma. The control solution contained non-
carbonated water (Acqua Panna, Nestlé, Germany) 
filled into clean empty CB12 bottles provided by, 
and relabelled at, MEDA (Radebeul, Germany). All 
treatments were administered by rinsing 10 ml in the 
mouth for 30 s, corresponding to the user instructions 
for CB12.
Study protocol
The study had a randomized, double-blind, controlled, 
cross-over design. Subjects were randomised 1:1 to 
one of two groups, with three treatment periods in 
each group; Group 1: CB12-water–water and Group 2: 
water-CB12–CB12. The second period of each sequence 
was replicated to estimate a potential carry over effect, 
and there was a 5 d washout between treatments.
Oral concentrations of hydrogen sulphide, methyl 
mercaptan and dimethyl sulphide were measured 
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using an OralChroma gas chromatograph (ABI Med-
ical). Total concentration of oral VSCs was assessed 
using a RH-17 Halimeter (Ansyco). Both the Halim-
eter and OralChroma were calibrated by the respec-
tive manufacturer prior to the study. The intensity 
of bad breath was assessed by a trained odour judge 
using the 0–5 organoleptic scale by Rosenberg (modi-
fied by Greenman): 0  =  no odour; 1  =  barely notice-
able odour; 2  =  slight odour; 3  =  moderate odour; 
4  =  strong odour; 5  =  very strong odour (satur-
ation) [27, 28]. All assessments were made at base-
line, 12 h after the first rinse following a night’s sleep 
(i.e. 12 h overnight effect), and 12 h after the second 
rinse (i.e. 12 h daytime effect). Total VSC concentra-
tion was also assessed at screening. A single reading 
was taken at each time point for OralChroma assess-
ments. Three readings were taken at each time point 
for Halimeter assessment and the median recorded.
Environment standardization
All study treatments were administered under 
supervision of the investigator’s staff, so separate 
compliance assessment was not required. To enable 
investigators to be blinded during assessments 
they were not allowed to be present during 
administrations. Subjects were present at the study 
site from early evening, approximately 3 h (for Period 
1 approximately 27 h) before first administration 
and up to 14 h after second administration of 
study treatment within each period, and stayed 
on the study ward from the time of admission to 
the last measurement. Subjects were instructed to 
refrain from their usual dental and mouth hygiene 
procedures on the day of admission. No changes in 
oral hygiene practices were permitted during the 
study and the consumption of foods associated with 
oral malodour (such as garlic, onions or alcohol) was 
not allowed on study days or in the preceding 48 h. 
Smoking was not allowed during the study period, 
and consumption of sweets or lozenges containing 
agents with impact on the oral microbiota (e.g. 
antimicrobial or breath-refreshing effect) was not 
allowed on screening visit or study days, or in the 
preceding 48 h. Subjects were also asked to fast for at 
least 3 h before admission to the clinical unit and VSC 
baseline assessments, for at least 12 h from first dosing 
to VSC assessments and organoleptic scoring in the 
morning and for at least 3 h prior to the evening VSC 
assessments and organoleptic scoring.
Meals and amount of beverages were standardized 
throughout the study. Subjects received a standardized 
meal prior to the first mouth rinse, a breakfast after 
morning assessments prior to the 2nd mouth rinse, 
lunch at approx. 4 h and a snack 8 h after the 2nd mouth 
rinse. Moreover, intake of 500 ml non-carbonated 
water was allowed from 1 h after the first mouth rinse 
until 3 h before morning assessments, and a further 
1500 ml permitted from 1 h after the second mouth 
rinse to 3 h before evening assessments following the 
2nd mouth rinse. No other beverages were permitted.
Safety
All adverse events (AEs) were recorded and classified. 
AEs were considered treatment emergent (TEAE) 
when occurring from the first administration of study 
treatment (0 h) until at latest 24 h after the second 
administration of study treatment. AEs occurring or 
worsening after that period were not analysed as TEAEs, 
but were considered separately as AEs.
Statistical analysis
Based on effect size and variances from preliminary 
studies [19, 20] it was estimated that 17 subjects per 
group would be required to achieve an overall power 
of 95% (probability to achieve the two primary and the 
key secondary endpoint—see below) with a one-sided 
α level of 2.5%. A drop-out rate of 15% was assumed. 
The intention-to-treat (ITT) population was defined as 
all subjects randomised and exposed to study treatment 
who had at least one follow-up assessment of efficacy. 
The per-protocol-population was a subset of the ITT 
population excluding subjects with major protocol 
violations. The ITT was the primary population for all 
study end points.
The primary efficacy measures were change in 
hydrogen sulphide and methyl mercaptan concen-
trations from baseline to 12 h after the first rinse with 
either CB12 or water (i.e. 12 h overnight effect). The key 
secondary outcome measure was change in OLS over 
the same time period.
Each of these endpoints were tested hierarchically in 
that order to maintain an overall one-sided type I error 
level at α  =  2.5%. Logarithms of 12 h measurements of 
the primary variables were analysed by baseline-adjusted 
ANCOVAs, with treatment, treatment sequence, period 
and carry-over (effect of prior period) as fixed effects, and 
the logarithm of the period baseline as a continuous covar-
iate. Due to the use of log-transformation, 0-values were 
replaced with 1 as the lowest detectable value by the chro-
matograph. The covariance matrix among periods was 
left unspecified and was allowed to vary among treatment 
sequences. Satterthwaite approximation was used for the 
degrees of freedom. Missing values were not replaced. OLS 
was analysed with the same ANCOVA model but without 
logarithmic calculus and baseline adjustment.
Primary and key secondary efficacy variables 
assessed 12 h after the second rinse (i.e. 12 h daytime 
effect) were classified as secondary efficacy outcomes. 
Other secondary efficacy variables were dimethyl sul-
phide and VSC concentrations 12 h after each mouth 
rinse (i.e. both overnight and daytime effect). All of 
these secondary variables were analysed by the same 
ANCOVA model as described for the primary efficacy 
parameters. Safety analyses were carried out for all ran-
domised subjects who received at least one dose of study 
treatment (the safety population).
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Results
Subject disposition and characteristics
A total of 86 subjects were screened and 34 were 
included in the study (figure 1). Two subjects were 
withdrawn from the study after the first treatment 
period, one for an adverse event (respiratory infection) 
and one for non-adherence to study procedure. Both 
were excluded from the per protocol population (but 
not from the ITT population). No other major protocol 
deviations occurred.
Subject baseline characteristics are presented in 
table 1. Continual mouth odour was reported in 12 
(35.3%) subjects, 10 (29.4%) reported problems in 
the morning and evening and 12 (35.3%) reported 
problems in the morning only. Almost all subjects 
(97%) already used mouth odour products. Subjects 
had variable degrees of tongue coating (mean Winkel 
score/index 4.3) and caries (mean DMF-T index 12). 
Mean VSC concentrations at screening were 208.6 
ppb in treatment group 1 and 300.8 ppb in Group 2 
(table 2). The difference was largely due to one subject 
who had an extremely high value (1572 ppb).
Volatile sulphur compounds
Compared to water, CB12 provided a significantly 
greater reduction in oral concentrations of hydrogen 
sulphide (Diff:  −1.409; 95% CI  −1.826, −0.993; 
p  <  0.0001; figure 2(A)) and methyl mercaptan 
(Diff:  −1.054; 95% CI:  −1.420, −0.688; p  <  0.0001; 
figure 2(B)) 12 h after the first rinse (i.e. overnight 
effect). Subjects who rinsed with water experienced 
marked overnight increases in oral concentrations 
of both hydrogen sulphide and methyl mercaptan, 
which was not the case with CB12 (figures 2(A) and 
(B)). The effect on both of these variables was still 
present 12 h after the second treatment, with CB12 use 
associated with a significantly greater reduction in oral 
concentration of hydrogen sulphide (Diff:  −1.706; 
95% CI:  −2.257, −1.155; p  <  0.0001) and methyl 
mercaptan (Diff:  −1.566; 95% CI:  −2.200, − 0.933; 
p  <  0.0001) compared to water (figures 2(A) and (B)).
CB12 also induced a significantly greater reduction 
in oral dimethyl sulphide concentration compared to 
water both 12 h after the first rinse (Diff:  −0.757; 95% 
CI:  −1.153, −0.356; p  =  0.0003) and 12 h after the 
second rinse (Diff:  −0.849; 95% CI:  −1.335, −0.362; 
p  =  0.0007) (figure 2(C)). Similarly, CB12 induced a 
significantly greater reduction than water in total VSC 
concentration for both the 12 h overnight assessment 
(Diff:  −0.503; 95% CI:  −0.655, −0.352; p  <  0.0001) 
and the 12 h daytime assessment (Diff:  −0.509; 95% 
CI:  −0.676, −0.342; p  <  0.0001) (figure 2). For each 
variable the three treatment periods showed similar 
time courses.
Organoleptic assessment
Subjects who rinsed with CB12 experienced a 
significantly greater 12 h overnight reduction in mean 
OLS than those who rinsed with water, across the 
three treatment periods (Diff:  −0.5; 95% CI:  −0.9, 
−0.1; p  =  0.0042). CB12 subjects experienced an 
OLS reduction from 3.0 (SD 0.6) at baseline to 2.5 
(SD 0.7) 12 later. Conversely, subjects who rinsed with 
water experienced no reduction in OLS 12 h later, 
remaining at their baseline OLS score of 2.8 (SD 0.7). 
Figure 1. Subject disposition.
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CB12 induced continued improved in OLS 12 h after 
the second rinse (i.e. 12 h day time effect), reducing 
the OLS to 2.4 (SD 0.6), compared to 2.6 (SD 0.8) for 
those in the water group (Diff:  −0.3; 95% CI:  −0.7, 
0.1; p  =  0.0458). The OLS assessments in this study 
were not very discriminative (baseline measurements 
showed values between 2 (lowest value) and 4 (highest 
value) leading to low correlations of objective and 
subjective assessments (R 0.48 for VSC Halimeter/OLS; 
R 0.24 for H2S OralChroma/OLS).
For all variables assessed, broadly similar findings 
were found irrespective of when intra-oral halitosis was 
predominantly experienced (i.e. continuously, morn-
ing & evening, or morning only; data not shown).
Safety
Six subjects reported a TEAE following CB12, and five 
subjects following water (table 3). Two of the TEAEs 
were considered to be related to CB12 administration: 
application site reaction and dysgeusia (n  =  1 
each; 2.9%). The most frequently reported TEAE 
was headache, reported by four subjects following 
CB12 and four subjects following water. No causal 
relationship between the occurrence of headache 
and the administration of the study treatments was 
seen, and headache was assessed as unlikely to be an 
adverse reaction. Vomiting was reported in one subject 
following water. There were no serious AEs. One subject 
discontinued treatment due to a wisdom tooth extraction.
Discussion
Halitosis can cause a significant social burden [6, 29, 30]. 
Satisfactory treatment, such as use of anti-bacterial 
mouthwashes, is considered beneficial to combat bad 
breath and has a positive impact on both social life 
and self-confidence [2, 31]. From a clinical perspective 
the duration of the VSC-reducing effect is of high 
interest. Our aim was to assess the long-term efficacy 
of CB12 in a well-controlled clinical trial setting using 
both objective and subjective measures of intra-oral 
halitosis. The results showed that CB12 effectively 
combated halitosis, and reduced the VSCs associated 
with it, for up to 12 h.
For the testing of VSC-reducing measures in breath 
malodour research, Yaegaki et al recommend a short-
term experiment in a cross-over design [15]. Based on 
their research they concluded that short-term stud-
ies are preferable in terms of standardisation because 
oral levels of VSCs show circadian variations [32] and 
are influenced by a variety of factors such as eating. 
However, short-term testing has no or limited ability 
to predict the long-lasting effect of a treatment, nor 
the cumulative effects of multiple treatments. For the 
current study, a highly standardized environment was 
chosen. All participants were treated, and then stayed in 
the study ward for 24 h under the supervision of study 
staff, with controlled meals. Study procedures were 
performed in accordance with a protocol that reflected 
Table 1. Subject baseline characteristics.
Sex, n (%) Male 17 (50)
Age, mean (range), years 44.2 (22–73)
BMI, mean (range), kg m−2 25.8 (18–38.6)
DMFT index, mean (range) 12 (0–23)
Total Winkel score, mean (range) 4.3 (2–10)
Dietary variables, n (%)
 Coffee drinkers 28 (82.4)
 Non-coffee drinkers 6 (17.6)
 Light alcohol drinkers 24 (70.6)
 Non-drinkers 10 (29.4)
 Daily meat consumption 9 (26.5)
 Occasional meat consumption 18 (52.9)
 Vegetarian/vegan 2 (5.8)
Concomitant treatment, n (%) 11 (32.4)
 Analgesicsa 3 (8.8)
 Thyroid therapy 3 (8.8)
 Anti-inflammatory/rheumatoid products 2 (5.9)
Current use of products for mouth odour, 
n (%)
33 (97)
 Mouth rinse products 23 (67.7)
 Chewing gum 23 (67.7)
 Dental floss 19 (55.9)
 Lozenges 17 (50)
Mouth odour history, n (%)
 Continuous mouth odour 12 (35.3)
 Problems in morning and evening 10 (29.4)
 Problems in the morning only 12 (35.3)
BMI: body mass index; DMFT: decayed, missing, and filled teeth.
a Only reported where incidences  >5%.
Table 2. Screening with the Halimeter for included subjects.
Treatment  sequence N
VSC concentration (ppb)
Mean (SD) Median (IQR)
CB12/Water/Water 18 208.6  
(100.00)
168.3  
(276.0, 479)
Water/CB12/CB12 16 300.8  
(346.13)
218.8  
(248.0, 1572)
All 34 252.0  
(248.58)
188.5  
(265.5, 1572)
VSC: volatile sulphur compound; ppb: parts per billion;  
SD: standard deviation; IQR: inter-quartile range.
Table 3. Adverse events.
CB12  
(N  =  34)
Water 
(N  =  32)
n (%) n (%)
Serious AEs 0 (0) 0 (0)
Treatment-emergent AEs
Application site reaction 1 (2.9) 0 (0)
Dysgeusia 1 (2.9) 0 (0)
Fatigue 1 (2.9) 0 (0)
Headache 4 (11.8) 4 (12.5)
Vomiting 0 (0) 1 (3.1)
AE: adverse event.
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Figure 2. (A) Hydrogen sulphide, (B) methyl mercaptan, (C) dimethyl sulphide and (D) total VSC concentrations at baseline, 12 h 
after first rinse and 12 h after 2nd rinse of CB12 or water in subjects (n  =  34) with halitosis of intra-oral origin. * p  <  0.0001 versus 
water; †p  =  0.0003 versus water; ‡p  =  0.0007 versus water.
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instruction-compliant real-world use, and the study 
was carried out to a rigorous randomized controlled 
trial design, and in line with Good Clinical Practice 
requirements. Other influencing factors were also 
tightly controlled.
In the current study, a clear, durable and statistically 
significant effect on intra-oral halitosis after instruc-
tion-compliant use of CB12 (i.e. morning and evening 
rinse) was observed for all primary and key secondary 
endpoints. CB12 showed significantly greater efficacy 
over water in reducing oral levels of hydrogen sulphide, 
methyl mercaptan, dimethyl sulphite and total VSC 
concentrations, with a 12 h duration of effect. This 
effect was apparent when assessed overnight (i.e. 12 h 
after the first rinse) and during the day (i.e. 12 h after 
the second rinse), thus confirming that 24 h breath-
odour control is achievable with instruction compliant 
use of CB12. The overnight 12 h duration of effect of 
CB12 is particularly relevant for sufferers, as maximum 
intensity of halitosis can occur in the mornings due to 
a reduction in saliva flow combined with an accumu-
lation of VSCs due to bacterial re-growth overnight; 
a problem for approximately 65% of subjects in this 
study. A confirmed 12 h duration of effect during the 
day-time is also relevant for individuals with intra-oral 
halitosis, providing confidence of fresh breath during 
the day, when social interactions are maximised.
For the organoleptic assessment of halitosis per-
formed by an experienced judge, a statistically signifi-
cant difference (p  =  0.0043) was observed between the 
CB12- and water-treated subjects for the 12 h overnight 
assessment, the key secondary efficacy parameter. Water-
treated subjects showed increased morning values, whilst 
CB12-treated subjects had decreased scores. Again, these 
results are of particular importance to those subjects who 
reported morning bad breath. However, the absolute 
reduction in OLS showed that halitosis was present after 
12 h, and the reduction compared to baseline appeared 
small. The study design did not allow for any judge-
ment on the development of halitosis levels from base-
line (directly after application up to the end of the 12 h 
period), or on the effect after 12 h, but it can be assumed 
that higher reductions were present in this period.
Instrumental measures have been widely included in 
the diagnostic procedures for halitosis. OralChroma gas 
chromatography provides an objective measure of hali-
tosis and has shown good correlation with OLS in former 
investigations [13, 14]. However, as OLS assessments in 
this study were not very discriminative, the correlations 
of objective and subjective assessments were low. The 
Halimeter is also used as a measure of halitosis, but is 
limited by its insensitivity to mid- to low-level concentra-
tions of VSCs; this sensitivity is even lower for dimethyl 
sulphide [13, 33]. Dimethyl sulphide levels do not always 
correlate well with OLS [13, 33]; thus dimethyl sulphide 
was chosen as a secondary variable in the current study.
The short-term effect of CB12 has been confirmed 
in previous studies [20, 21, 24, 25]. These studies 
showed CB12 to be effective in the reduction of halitosis, 
and superior to both placebo and a number of differ-
ent mouthwashes for a range of halitosis-related out-
come measures. The results of the present study now 
confirm the long-term effect of CB12 in a robust and 
well-controlled study design. How CB12 maintains its 
12 h duration of effect is a subject of debate. Its active 
ingredients, zinc acetate and chlorhexidine, operate by 
different mechanisms; Zinc interacts with the sulphur in 
the substrate or in precursors of VSC, forming insoluble 
sulphides (since it has an affinity for sulphur and oxidises 
sulfhydryl groups [34]) and may also directly inhibit 
thiol proteinase activity related to VSC production [35]. 
Chlorhexidine is known to be a strong denaturing agent. 
A splitting of disulphide bonds would be beneficial as 
oral bacteria mainly contain desulphydrases [36]. The 
splitting of disulphide bonds could provide an explana-
tion for the observed marked and long-lasting effect of 
CB12. Furthermore, Young and colleagues [36] showed 
a synergy between zinc and chlorhexidine; this combina-
tion provided a reduction of  >95% of the baseline VSC 
concentration even 9 h after rinsing. The authors con-
cluded that under normal conditions (without cysteine 
challenges) it may be safe to conclude that the mouth 
rinse (CB12) could be effective for 12 h or more [36]. 
Indeed, Thrane et al [19] showed that CB12 effectively 
inhibited oral VSC production for over 12 h, both with 
and without cysteine challenge, ‘likely due to a syner-
gistic effect of zinc and chlorhexidine on VSC’, further 
corroborating the results of the present study.
CB12 was well tolerated; the only AEs considered 
likely to be adverse drug reactions were dysgeusia and 
application site reaction in one subject each. Headache 
was reported in 11.8% of subjects following CB12 and 
12.5% following water. Dietary restrictions in this 
study included refraining from all xanthine-contain-
ing beverages and food (e.g. coffee, black and green tea, 
cola, any chocolate) for the entire duration of the in-
house stay. It is therefore possible that the headaches 
were a result of caffeine withdrawal.
A potential limitation of the study was that CB12 was 
compared with water. There is a possibility that subjects 
could distinguish the two treatments by taste. However, 
this is unlikely to have led to bias as the odour judges 
were fully blinded, and subjects were told not to com-
municate impressions of smell and taste to ensure that 
blinding was preserved. Recruitment of individuals with 
confirmed intra-oral halitosis was a strength of this study, 
unlike others which have often relied on volunteers with 
morning breath or used cysteinyl challenge. Indeed, the 
strict inclusion and exclusion criteria relating to intra-
oral halitosis explain the relatively high screen failure 
rate in our study (60.5%). Additionally, in the current 
study all efforts were made to standardize the environ-
ment, removing as much variability as possible, in order 
to prove a direct cause and effect relationship between 
CB12 use and intra-oral halitosis abatement for 12 h. 
Finally, results obtained from the gold-standard subjec-
tive measure of intra-oral halitosis assessment (i.e. OLS) 
were confirmed using objective VSC assessments.
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In conclusion, this study confirms that rinsing with 
CB12, in accordance with its instructions for use, led to 
a statistically significant reduction in intra-oral halito-
sis, assessed both subjectively and objectively, with an 
effect lasting for 12 h. Use of CB12 twice daily (morning 
and evening) provided 24 h protection from VSC pro-
duction associated with intra-oral halitosis.
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